Hearing loss in cystic fibrosis

International Journal of Pediatric Otorhinolaryngology

Volumn 74, Issue 5, 2010, Pages 469-473

  Martins, Luciana M N ^a   Camargos, Paulo A M ^a   Becker, Helena M G ^a   Becker, Celso G ^a   Guimarães, Roberto E S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Aminoglycosides; Cystic fibrosis; Sensorineural hearing loss

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN;

ADOLESCENT; ADULT; ARTICLE; AUDITORY SCREENING; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DESCRIPTIVE RESEARCH; DISTORTION PRODUCT OTOACOUSTIC EMISSION; DRUG USE; FEMALE; HEARING LOSS; HIGH RISK POPULATION; HUMAN; INFANT; INTRAUTERINE INFECTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; OTORHINOLARYNGOLOGY; PERCEPTION DEAFNESS; PRESCHOOL CHILD; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; QUESTIONNAIRE; SCHOOL CHILD;

ADOLESCENT; AMIKACIN; ANTI-BACTERIAL AGENTS; AUDIOMETRY, PURE-TONE; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; GENTAMICINS; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT; MALE; OTOACOUSTIC EMISSIONS, SPONTANEOUS;

EID: 77951641204     PISSN: 01655876     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijporl.2010.01.021     Document Type: Article

References (22)

1. Aitken L.M., Fiel S.B. Cystic fibrosis. Dis. Month 1993, 39:1-52.
2. Haddad J., Gonzalez C., Kurland G., Orenstein D.M., Casselbrant M.L. Ear disease in children with cystic fibrosis. Arch. Otolaryngol. Head Neck Surg. 1994, 120:491-493.
3. Ozcelik T., Ozgirgin N., Ozcelik U., Gocmen A., Gurcan B., Kiper N. Auditory nerve-brainstem responses in cystic fibrosis patients. Int. J. Pediatr. Otorhinolaryngol. 1996, 35:165-169.
4. Jorrisen M., Boeck K., Feenstra L. Middle ear disease in cystic fibrosis. Int. J. Pediatr. Otorhinolaryngol. 1998, 43:123-128.
5. Kimberley B.P., Brown D.K., Eggermont J.J. Measuring human cochlear traveling wave delay using distortion product emissions phase responses. J. Acoust. Soc. Am. 1993, 94:1343-1350.
6. Mulheran M., Degg C. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. Br. J. Audiol. 1997, 31:5-9.
7. Mulheran M., Degg C., Burr S., Morgan D.W., Stableforth D.E. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob. Agents Chemother. 2001, 45:2052-2059.
8. Cheng A.G., Johnston M.M., Luz J., Uluer A., Fligor B., Licameli G.R., et al. Sensorioneural hearing loss in patients with cystic fibrosis. Otolaryngol. Head Neck Surg. 2009, 141:86-90.
9. Suryanarayanan R., Taylor P., Tan K. Absence of acute tobramycin ototoxicity in both once or twice daily treatment regimes in patients with cystic fibrosis. Clin. Otolaryngol. 2005, 30:577.
10. Denoyelle F., Garabedian E.N., Sardet A., Tournier G., Belitty A. Atteinte de la sphere ORL dans la mucoviscidose. Ann. Otolaryngol. Chir. Cervicofac. 1990, 107:200-203.
11. Piltcher O.B., Teixeira V.N., Oliveira M.W., Scattolin I., Piltcher S.L. The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clinicas de Porto Alegre. Int. J. Pediatr. Otorhinolaryngol. 2003, 939-941.
12. Sone M., Schachern P.A., Paparella M.M. Loss of spiral ganglion cells as primary manifestation of aminoglycoside ototoxicity. Hear. Res. 1998, 115:217-223.
13. Hinojosa R., Nelson E.G., Lerner A.S., Redleaf M.I., Schramm D.R. Aminoglycoside ototoxicity: a human temporal bone study. Laryngoscope 2001, 111:1797-1805.
14. Zheng Y., Schachern P.A., Sone M., Paparella M.M. Aminoglycoside ototoxicity. Otol. Neurotol. 2001, 22:266-268.
15. International Organisation for Standardisation Acoustics-Thresholds of Hearing by Air Conduction as a Function of Age and Sex for Otologically Normal Persons. ISO 7029 1984, International Organisation for Standardisation, Geneva, Switzerland.
16. Robinson D.W. Threshold of hearing as a function of age and sex for the typical unscreened population. Br. J. Audiol. 1988, 22:5-20.
17. Kimberley B.P. Applications of distortion-product emissions to an otological practice. Laryngoscope 1999, 109:1908-1917.
18. Chan K.H. Sensorioneural hearing loss in children. Otolaryngol. Clin. N. Am. 1994, 27:473-486.
19. Brown A.M., MCDowell B., Forge A. Acoustic distortion products can be used to monitor the effects of chronic gentamicin treatment. Hear. Res. 1989, 42:143-156.
20. Stavroulaki P., Vossinakis I., Dinopoulou D., Doudounakis S., Adamopoulos G., Apostolopoulos N. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. Arch. Otolaryngol. Head Neck Surg. 2002, 128:150-155.
21. Katbama B., Homnick D.N., Marks J.H. Effects of chronic Tobramycin treatment on distortion product otoacoustic emissions. Ear Hear. 1999, 20:393-403.
22. Conrad D.J., Stenbit A.E., Zettner E.M., Wich I., Eckhardt C., Hardiman G. Frequency of mitochondrial 12s ribosomal RNA variants in an adult cystic fibrosis population. Pharmacogenet. Genomics 2008, 18:1095-1102.